SEC Form 4 · accession 0001387131-15-000861
Ohr Pharmaceutical Inc · OHRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samuel Backenroth
Officer — Chief Financial Officer
Period of report
Mar 10, 2015
Accepted (ET)
Mar 12, 2015 · 4:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001173281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per share | holding | — | — | — | 6,199 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionF5,F4 | $10.14 | Mar 10, 2015 | A | 60,000 | A | Mar 10, 2015 | Mar 10, 2020 | Common Stock | 60,000 | 60,000 | D |
| OptionF1 | $1.50 | holding | — | — | — | Apr 12, 2010 | Apr 12, 2015 | Common Stock | 66,667 | 66,667 | D |
| OptionF2 | $1.71 | holding | — | — | — | Mar 9, 2014 | Mar 9, 2017 | Common Stock | 133,333 | 133,333 | D |
| OptionF3 | $10.11 | holding | — | — | — | Feb 3, 2014 | Feb 3, 2017 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1All exercisable.
- F2All exercisable.
- F3125,000 options are currently unexercisable; half will become exercisable February 3, 2016 and half will become exercisable February 3, 2017.
- F445,000 options are currently unexercisable; 1/3rd will become exercisable on each of March 10, 2016, March 10, 2017 and March 10, 2018.
- F5Options granted pursuant to registrant's 2014 Stock Incentive Plan.